9-cis-Retinoic Acid
9-cis-Retinoic Acid
9-cis Retinoic Acid (C134191 ≥98%, C305934 ≥95%) is a biologically active form of vitamin A and serves as an endogenous ligand for retinoid X receptors (RXRs). Like other retinoids, it also activates retinoic acid receptors (RARs). Retinoids are critical regulators of numerous cellular processes, including cell proliferation, differentiation, immune response, bone tissue development, and tumor suppressor gene activation.
9-cis Retinoic Acid was among the earliest retinoids used clinically. It has demonstrated therapeutic benefit in conditions such as Kaposi’s sarcoma and chronic hand eczema, and shows potential in treating other dermatological disorders like pityriasis rubra pilaris.
In oncology, 9-cis Retinoic Acid also displays anticancer activity, particularly in hormone-dependent cancers. Adrenocortical carcinoma, which is associated with reduced endogenous retinoic acid production, responds to 9-cis Retinoic Acid treatment through decreased cell viability, reduced steroid hormone secretion, and disruption of cell cycle regulation. In animal models, administration led to suppressed tumor growth. In breast cancer models, the compound inhibited proliferation by modulating the interaction between RXRα and replication factor C3 (RFC3)—a mechanism also linked to its effects on embryonic cell proliferation.
Beyond cancer biology, 9-cis Retinoic Acid exerts antioxidative and neuroprotective properties. In methamphetamine-induced neurotoxicity models, it improved locomotor activity, restored striatal tyrosine hydroxylase levels, and reduced dopaminergic neuron loss. In Parkinson’s disease models, it improved motor performance and alleviated neurodegenerative symptoms.
Retinoids also play key roles in immune regulation. In cellular models, 9-cis Retinoic Acid enhanced immune cell adhesion through both integrin-dependent and integrin-independent pathways. Additionally, animal studies demonstrated that it promotes lymphatic vessel proliferation and regeneration, reducing lymphedema symptoms.
Aladdin also supplies a variety of related retinoids for research use, including:
Aladdin catalog | Product name | purity |
All-trans Retinol | ≥95% ≥97.5%(HPLC) ~3100 U/mg 10mM in DMSO | |
13-cis Retinoic Acid | ≥98% 10mM in DMSO | |
Retinyl Palmitate | 1,700,000 USP units /g 2mM in DMSO | |
Retinyl Acetate | for cell culture synthetic, matrix dispersion, 475,000-650,000 USP units/g 10mM in DMSO from Synthetic crystalline solid or supercooled liquid USP Ph.Eur. | |
Etretinate | ≥96% 10mM in DMSO | |
Acitretin | ≥98% 10mM in DMSO |
References:
1. Dawson, MI and Xia Z. Biochim Biophys Acta, 2012 Jan. 1821(1): 21-56.
2. King T, McKenna J, and Alexandroff AB. Patient Prefer Adherence, 2014 Nov. 8:1629-34.
3. Miles SA, Dezube BJ, Lee JY, et al. AIDS. 2002 Feb 15;16(3):421-9.
4. Armann PM, Susic M, Glüder F. Acta Derm Venereol. 2014 Jul. [Epub ahead of print].
5. Szabó DR, Baghy K, Szabó PM, et al. Cell Mol Life Sci. 2014 Mar;71(5):917-32.
6. Maeng S, Kim GJ, Choi EJ, et al. Mol Endocrinol. 2012 Nov;26(11):1821-35.
7. Reiner DJ, Yu SJ, Shen H,, et al. Neurotox Res. 2014 Apr;25(3):248-61.
8. Yin LH, Shen H, Diaz-Ruiz O, et al. BMC Neurosci. 2012 Oct 6;13:120.
9. Whelan JT, Chen J, Miller J, et al. J Nutr Biochem. 2013 May;24(5):832-41.
10. Choi I, Lee S, Kyoung Chung H, et al. Circulation. 2012 Feb 21;125(7):872-82.
Aladdin: https://www.aladdinsci.com/